Search Images Maps Play YouTube News Gmail Drive More »
Sign in
Screen reader users: click this link for accessible mode. Accessible mode has the same essential features but works better with your reader.

Patents

  1. Advanced Patent Search
Publication numberUS9592254 B2
Publication typeGrant
Application numberUS 14/162,915
Publication date14 Mar 2017
Filing date24 Jan 2014
Priority date6 Feb 2013
Also published asCA2899724A1, CN104994893A, EP2953658A1, US20140220095, US20170209619, WO2014123703A1
Publication number14162915, 162915, US 9592254 B2, US 9592254B2, US-B2-9592254, US9592254 B2, US9592254B2
InventorsGary Monteiro, Christopher T. Wagner, Neil L. Rodriguez, Aubrey Irene Delossantos
Original AssigneeLifecell Corporation
Export CitationBiBTeX, EndNote, RefMan
External Links: USPTO, USPTO Assignment, Espacenet
Methods for localized modification of tissue products
US 9592254 B2
Abstract
Methods for treating tissue matrices and tissue matrices produced according to the methods are provided. The methods can include treating select portions of a tissue matrix with a cross-linking agent and/or a proteolytic enzyme to produce a tissue matrix with variable mechanical and/or biological properties.
Images(8)
Previous page
Next page
Claims(11)
What is claimed is:
1. A method for treating a tissue matrix, comprising:
selecting a collagen-containing tissue matrix;
providing a solid surface having one or more channels;
contacting the tissue matrix with the surface; and
causing fluid containing a proteolytic enzyme to flow through the channels and contact select portions of the tissue matrix defined by the location of the channels to produce a tissue matrix having mechanical properties that vary across the tissue matrix.
2. The method of claim 1, wherein the tissue matrix is an acellular tissue matrix.
3. The method of claim 1, wherein the tissue matrix comprises a dermal tissue matrix.
4. The method of claim 1, wherein the tissue matrix is derived from a tissue selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.
5. The method of claim 1, wherein the one or more channels have at least one of a serpentine pattern, a web-like pattern, a circular pattern, a grid pattern, and a linear pattern.
6. The method of claim 1, wherein the enzyme is bromelain.
7. The method of claim 1, wherein the enzyme is selected from bromelain, papain, ficin, actinidin, or combinations thereof.
8. The method of claim 1, further including treating the tissue matrix to remove at least some of the cells and cellular components from the tissue matrix.
9. The method of claim 8, including removing all the cells and cellular components from the tissue matrix.
10. A method for treating a tissue matrix, comprising: selecting a collagen-containing tissue matrix; and contacting a select portion of the tissue matrix with a proteolytic enzyme to produce a tissue matrix having different mechanical properties in the select portion than in a portion of the tissue matrix that was not contacted, wherein contacting the select portion of the tissue matrix with a proteolytic enzyme comprises providing a solid surface having one or more channels configured to allow fluid to flow therethrough; contacting the tissue matrix with the surface; and causing fluid containing the proteolytic enzyme to flow through the one or more channels.
11. The method of claim 10, wherein contacting the select portion of the tissue matrix with a proteolytic enzyme comprises applying a fluid containing a proteolytic enzyme to the select portion.
Description

This application claims priority under 35 U.S.C. §119 to U.S. Provisional Patent Application 61/761,298, which was filed on Feb. 6, 2013, and which is incorporated by reference in its entirety.

The present disclosure relates to tissue matrices, and more particularly, to methods for localized modification of mechanical and/or biological properties of tissue matrices.

Various tissue-derived products are used to regenerate, repair, or otherwise treat diseased or damaged tissues and organs. Such products can include intact tissue grafts and/or acellular or reconstituted acellular tissues (e.g., acellular tissue matrices from skin, intestine, or other tissues, with or without cell seeding). Such products generally have mechanical properties determined by the tissue source (i.e., tissue type and animal from which it originated) and the processing parameters used to produce the tissue products. Since tissue products are often used for surgical applications and/or tissue replacement or augmentation, the mechanical and biological properties of the tissue products are important. For example, tissue products must be able to provide suitable mechanical support (e.g., to close a tissue defect), while allowing tissue in-growth and regeneration. In some cases, however, it may be desirable to modify the mechanical and/or biological properties of tissue products. Furthermore, in order to improve the performance of tissue products for specific applications, it may be desirable to produce tissue products that have variable mechanical and/or biological properties. Accordingly, the present disclosure provides devices and methods for localized modification of mechanical and/or biological properties of tissue products, including acellular tissue matrices.

SUMMARY

According to various embodiments, a method for treating a tissue matrix is provided. The method can comprise selecting a collagen-containing tissue matrix and cross-linking select portions of the tissue matrix to produce a tissue matrix having mechanical or biological properties that vary across the tissue matrix. In some embodiments, the tissue matrix is an acellular tissue matrix. In certain embodiments, the tissue matrix comprises a dermal tissue matrix. In other embodiments, the tissue matrix is derived from a tissue selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.

In some embodiments, the method comprises cross-linking select portions of the tissue matrix by applying a fluid containing a cross-linking agent to the select portions. In certain embodiments, applying a fluid containing a cross-linking agent to the select portions comprises providing a solid surface having one or more channels configured to allow fluid to flow therethough; contacting the tissue matrix with the surface; and causing fluid containing a cross-linking agent to flow through the channels. In various embodiments, the one or more channels have at least one of a serpentine pattern, a web-like pattern, a circular pattern, a grid pattern, and a linear pattern. In various embodiments, the cross-linking agent comprises at least one of gluteraldehyde, 1-Ethyl-3-[3-dimethylaminopropyl]carbodiimide hydrochloride (EDC), or genepin.

In various embodiments, a method for treating a tissue matrix is provided. The method can comprise selecting a collagen-containing tissue matrix and contacting select portions of the tissue matrix with a proteolytic enzyme to produce a tissue matrix having mechanical properties that vary across the tissue matrix. In some embodiments, the tissue matrix comprises a dermal tissue matrix. In other embodiments, the tissue matrix is derived from a tissue selected from fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue.

In some embodiments, contacting select portions of the tissue matrix with a proteolytic enzyme comprises applying a fluid containing the proteolytic enzyme to the select portions. In some embodiments, contacting select portions of the tissue matrix with a proteolytic enzyme comprises providing a solid surface having one or more channels configured to allow fluid to flow therethough; contacting the tissue matrix with the surface; and causing fluid containing the proteolytic enzyme to flow through the channels. In some embodiments, the one or more channels have at least one of a serpentine pattern, a web-like pattern, a circular pattern, a grid pattern and a linear pattern.

In certain embodiments, the enzyme is bromelain. In some embodiments, the enzyme is selected from bromelain, papain, ficin, actinidin, or combinations thereof.

In some embodiments, the method further includes treating the tissue matrix to removal at least some of the cells and cellular components from the tissue matrix. In some embodiments, the method includes removing all the cells and cellular components from the tissue matrix.

In various embodiments, tissue products produced according to any of the disclosed methods are provided.

In certain embodiments, a tissue product is provided. The tissue product can comprise an acellular tissue matrix derived from a collagen-containing tissue, wherein the tissue matrix comprises a flexible sheet, and wherein the tissue matrix comprises select regions of cross-linked or proteolytically digested material, and wherein the mechanical or biological properties of the tissue matrix vary across the flexible sheet.

DESCRIPTION OF THE DRAWINGS

FIGS. 1A-1B illustrate a device for microfluidic modification of a tissue product, according to certain embodiments.

FIG. 2 illustrates a device for microfluidic modification of a tissue product, according to certain embodiments.

FIG. 3 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical and/or biological properties, according to certain embodiments.

FIG. 4 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

FIG. 5 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

FIG. 6 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

FIG. 7 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

FIG. 8 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

FIG. 9 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

FIG. 10 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

FIG. 11 illustrates an acellular tissue matrix that has been treated to provide localized modification of mechanical properties and/or biological properties, according to certain embodiments.

DESCRIPTION OF CERTAIN EXEMPLARY EMBODIMENTS

Reference will now be made in detail to certain exemplary embodiments according to the present disclosure, certain examples of which are illustrated in the accompanying drawings. Wherever possible, the same reference numbers will be used throughout the drawings to refer to the same or like parts.

In this application, the use of the singular includes the plural unless specifically stated otherwise. In this application, the use of “or” means “and/or” unless stated otherwise. Furthermore, the use of the term “including”, as well as other forms, such as “includes” and “included”, is not limiting. Any ranges described herein will be understood to include the endpoints and all values between the endpoints.

The section headings used herein are for organizational purposes only and are not to be construed as limiting the subject matter described. All documents, or portions of documents, cited in this application, including but not limited to patents, patent applications, articles, books, and treatises, are hereby expressly incorporated by reference in their entirety for any purpose.

As used herein “tissue product” will refer to any human or animal tissue that contains extracellular matrix proteins. “Tissue products” can include acellular or partially decellularized tissue matrices, as well as decellularized tissue matrices that have been repopulated with exogenous cells.

Various human and animal tissues can be used to produce products for treating patients. For example, various tissue products are available for regeneration, repair, augmentation, reinforcement, and/or treatment of human tissues that have been damaged or lost due to various diseases and/or structural damage (e.g., from trauma, surgery, atrophy, and/or long-term wear and degeneration). Such products can include, for example, acellular tissue matrices, tissue allografts or xenografts, and/or reconstituted tissues (i.e., at least partially decellularized tissues that have been seeded with cells to produce viable materials).

For surgical applications, it is often desirable to produce tissue products that have certain mechanical properties. For example, the tissue product, which may include a sheet of material, should possess sufficient strength to withstand stresses during the intended use. Certain tissue products may be used to repair defects (e.g., hernias), to support surrounding tissues or implants (e.g., for breast augmentation and/or reconstruction), or to replace damaged or lost tissue (e.g., after trauma or surgical resection). Whatever the particular use, the tissue product should have sufficient strength, elasticity, and/or other mechanical properties to function until tissue regeneration and/or repair occurs.

Some tissue products, however, may be functionally improved by altering the mechanical properties of the products. For example, a number of acellular tissue matrix products are available, and often, such tissue matrices are in the form of a flexible sheet of material that has substantially uniform mechanical and/or biological properties over its entire surface area. For some indications, however, it may be desirable to alter the mechanical and/or biological properties of such tissue matrices such that the properties vary across the material. For example, in some embodiments, it may be desirable to strengthen, stiffen, weaken, or make more pliable select regions of a tissue product to produce a product having variable mechanical properties. In addition, in some embodiments, it may be desirable to modify certain elastic or viscoelastic properties of a tissue matrix, including, for example, the resistance to stretching at low deformation levels (e.g., toe-region mechanics).

It may be desirable to treat select regions of the tissue products to control the rate of degradation, cell in-growth, and/or vascularization after implantation. It is known that cross-linking can increase the resistance of tissue matrices to degradation by inflammatory cells within the body, and such increased resistance can slow the rate of weakening after implantation. Accordingly, in some embodiments, it may be desirable to provide localized cross-linking to provide areas of the tissue matrix that maintain their ability to provide mechanical support to an implantation site for longer times after implantation, while simultaneously providing sufficient tissue matrix mass to support normal tissue regeneration within uncross-linked portions of the tissue matrix.

The present disclosure provides methods for treating tissues to provide variable mechanical and/or biological properties along the length, width, or thickness of a tissue matrix. The disclosure also provides tissue products produced using the methods of treatments.

According to various embodiments, a method for treating a tissue matrix is provided. The method can comprise selecting a collagen-containing tissue matrix and cross-linking select portions of the tissue matrix to produce a tissue matrix having mechanical and/or biological properties that vary across the tissue matrix. In some embodiments, the tissue matrix is an acellular tissue matrix. In certain embodiments, the tissue matrix comprises a dermal tissue matrix.

In various embodiments, a method for treating a tissue matrix is provided. The method can comprise selecting a collagen-containing tissue matrix and contacting select portions of the tissue matrix with a proteolytic enzyme to produce a tissue matrix having mechanical properties that vary across the tissue matrix.

The tissue products according to the present disclosure can be selected to provide a variety of different biological and/or mechanical properties. For example, an acellular tissue matrix or other tissue product can be selected to allow tissue in-growth and remodeling to assist in regeneration of tissue normally found at the site where the matrix is implanted. For example, an acellular tissue matrix, when implanted on or into fascia or other soft tissue, may be selected to allow regeneration of the fascia or other soft tissue without excessive fibrosis or scar formation. In certain embodiments, the tissue product can be formed from ALLODERM® or STRATTICE™ (LIFECELL CORPORATION, Branchburg, N.J.), which are human and porcine acellular dermal matrices respectively. Alternatively, other suitable acellular tissue matrices can be used, as described further below. The tissues can be selected from a variety of tissue sources including skin (dermis or whole skin), fascia, pericardial tissue, dura, umbilical cord tissue, placental tissue, cardiac valve tissue, ligament tissue, tendon tissue, arterial tissue, venous tissue, neural connective tissue, urinary bladder tissue, ureter tissue, and intestinal tissue. The methods described herein can be used to process any collagenous tissue type and for any tissue matrix product. For example, a number of biological scaffold materials are described by Badylak et al., and the methods of the present disclosure can be used to treat those or other tissue products known in the art. Badylak et al., “Extracellular Matrix as a Biological Scaffold Material: Structure and Function,” Acta Biomaterialia (2008), doi:10.1016/j.actbio.2008.09.013.

In some cases, the tissue matrix can be provided as a decellularized tissue matrix. Suitable acellular tissue matrices are described further below. In other cases, the method can further include processing intact tissue to remove cells or other materials either before, after, or both before and after cross-linking or proteolytic treatment according to the present application. The tissues can be completely or partially decellularized to yield acellular tissue matrices or extracellular tissue materials to be used for patients. For example, various tissues, such as skin, intestine, bone, cartilage, nerve tissue (e.g., nerve fibers or dura), tendons, ligaments, or other tissues can be completely or partially decellularized to produce tissue products useful for patients. In some cases, these decellularized products can be used without addition of exogenous cellular materials (e.g., stem cells). In certain cases, these decellularized products can be seeded with cells from autologous sources or other sources to facilitate treatment. Suitable processes for producing acellular tissue matrices are described below.

In certain embodiments, tissue matrices can be treated to provide localized variation in mechanical and/or biological properties by contacting the tissue matrices with one or more cross-linking agents and/or proteolytic enzymes. Generally, the matrices can be treated by contacting selected portions of the tissue matrices with a fluid containing the agent or enzyme and under conditions (e.g., temperature and/or pH) and for a time sufficient to produce a desired degree of cross-linking and/or proteolysis.

The fluid containing cross-linking agents or enzymes can be applied to selected regions of the tissue matrix in a variety of ways. In certain embodiments, the fluid is made to flow in contact with the tissue matrix to permit contact with only those regions of the tissue matrix that are selected for modification. FIGS. 1A-1B illustrate a device 10 for microfluidic modification of tissue products, according to certain embodiments. As shown in FIG. 1A, the device 10 can include a rigid body with a bottom surface 12 and top surface 14, as well as a number of channels 16. When in use, the device 10 can be placed with the bottom surface 12 and channels 16 facing downward towards a rigid surface 15 (FIG. 1B). A tissue matrix 19 can be placed between the bottom surface 12 and the rigid surface 15 with sufficient pressure to substantially prevent flow of fluid through the tissue matrix 19 other than at regions surrounded by the channels 16. The fluid containing cross-linking agents or enzymes can be made to flow through the channels 16 via entrance and exit fluid supply tubings 18, 20. In some embodiments, each channel 16 can be connected to an individual supply tubing 18, 20, or one or more of the channels can be connected to supply tubing via manifolds, as long as a desired degree of fluid flow is achieved.

The channels 16 can have a variety of shapes, sizes and configurations. In general, the channels 16 should be spaced far enough apart to allow a seal to form between channels when placed in contact with a tissue matrix. Further, suitable channel widths can range from 1 micron to 5 cm, and suitable channel heights can range from 1 micron to 2 mm. In addition, the channel edges should be rounded or blunted to prevent tissue damage.

A number of different cross-linking agents and/or enzymes can be used to treat the tissue matrices. For example, suitable cross-linking agents can include gluturaldyhyde, EDC, genepin, aldehydes, and/or lysyl oxidase; and suitable enzymes can include sulfhydryl proteases such as bromelain. In addition, the enzymes can include bromelain, papain, ficin, actinidin, or combinations thereof. The enzymes and cross-linking agents can be purchased commercially; or enzymes can be extracted from fruit sources. For example, one source of bromelain is MCCORMICK MEAT TENDERIZER, but the enzymes can also be extracted from pineapple and/or purchased in a medical-grade formulation.

The enzymes can be contacted with the tissues to increase the pliability of the tissue without causing undesirable degradation in other mechanical and/or biological properties. For example, when a batch of materials is produced with or without the enzyme treatments discussed herein, the enzyme treatments will not produce an undesirable change in at least one of tensile strength, tear strength, suture strength, creep resistance, collagenase susceptibility, glycosaminoglycan content, lectin content, burst strength, thermal transition temperature, or combinations thereof. In some cases, an undesirable change is a statistically significant reduction any one of tensile strength, tear strength, suture strength, creep resistance, glycosaminoglycan content, lectin content, burst strength; an increase in collagenase susceptibility; or a change (upward or downward) in thermal transition temperature (as measure using differential scanning calorimetry).

In some cases, the enzymes are selected such that they cause site-specific cleavage of proteins within the tissues. For example, it has been found that treatment of porcine dermal materials with bromelain does not cause further alterations in the matrix structure after a certain amount of treatment. Therefore, treatment of dermis with bromelain does not cause further change in the matrix with prolonged exposure or after extended periods of time.

In addition, the enzymes and cross-linking agents can be applied to the tissues in a variety of suitable solutions. For example, bromelain has been found to be effective when applied to tissues in normal saline, but other suitable buffers (e.g., PBS) can be used.

The device 10 used to contact the tissue matrix 19 with enzymes and/or cross-linking agents can have a variety of different configurations. For example, as described in further detail below with respect to FIGS. 3-10, the tissue matrix 19 can be treated by cross-linking and/or treatment with proteolytic enzymes at a number of suitable locations to produce a pattern providing desired variations in mechanical and/or biological properties. FIG. 2 illustrates a device 10′ for microfluidic modification of tissue products, according to certain embodiments. As shown, the device 10′ again includes a rigid structure with channels 16′. In the embodiment of FIG. 2, however, the channels 16′ have a shape or pattern that is different than that of FIG. 1, thereby allowing contact of the cross-linking agent or proteolytic enzyme to produce a modified tissue matrix with a different configuration. Furthermore, the device 10′ has two openings 18′ and 20′, which provide passages for flow of fluid into and out of the channels 16′, rather than having multiple separate openings 18, 20, as with the device of FIG. 1. Any suitable number of openings may be used to provide adequate flow of fluid through channels 16, 16

The methods of the present disclosure can be used to modify mechanical and/or biological properties in a number of different locations. FIGS. 3-10 illustrate acellular tissue matrices that have been treated to provide localized modification of mechanical and/or biological properties, according to certain embodiments. In various embodiments, the tissue matrices can be treated to modify select regions of a sheet-like tissue matrix over regions having a serpentine pattern 32 (FIG. 3), a spiral pattern 42 (FIG. 4), linear patterns 52, 62 (FIGS. 5 and 6), curved patterns 72 (FIG. 7), along linear or longitudinally aligned patterns 82 in a cylindrically wrapped sheet 80 (FIG. 8), in a circular pattern 92 (FIG. 9), in a web-like pattern 102 (FIG. 10), or in a grid pattern 110 (FIG. 11).

The specific pattern of the region selected for localized cross-linking or proteolytic treatment can be selected for a variety of reasons. It is known that cross-linking can increase the resistance of tissue matrices to degradation by inflammatory cells within the body, and such increased resistance can slow the rate of weakening after implantation. Excessive cross-linking, however, can have adverse effects on cell infiltration and regeneration of normal tissue within the tissue matrix. Accordingly, in some embodiments, it may be desirable to provide localized cross-linking to provide areas of the tissue matrix that maintain their ability to provide mechanical support to an implantation site for longer times after implantation, while simultaneously providing sufficient tissue matrix mass to support normal tissue regeneration within uncross-linked portions of the tissue matrix.

Localized protease treatment may be used for a variety of reasons. For example, localized protease treatment can allow production of differing strength or other mechanical properties treating the tissue to make native stronger. In addition, production of tissue matrices with localized pliability may be to allow a surgeon to place tissue in small openings, including passing a tissue matrix through a laparoscopic incision or trocar. In addition, production of tissue with localized pliability can be beneficial to allow matching of compliances with natural tissues or to match anisotropic mechanical properties of tissues.

The specific pattern of localized treatment may be selected based on a desired implantation site or treatment method. For example, in various embodiments, the pattern may be selected to provide a treated tissue matrix having improved mechanical properties (e.g., higher yield strength) along dimensions that may be more likely to experience higher loads during use. For example, in the embodiments of FIGS. 3-6 and 9-10, the pattern may be selected to increase the strength of the sheet of tissue matrix along one or more axes parallel to the sheet of tissue matrix. Similarly, FIG. 7 illustrates a sheet of tissue matrix 70 that can include an upper convex surface 74 and lower convex surface 76, which may be well-suited for use in supporting a breast implant after breast reconstruction or augmentation, and the matrix 70 can be treated along lines 72 selected to increase the strength or elastic modulus of the matrix in direction that may be most likely to fail during use. Similarly, FIG. 8 illustrates a cylindrically shaped matrix 80 having a treatment pattern 82 along lines parallel to an axis of the matrix 80. The cylindrically shaped matrix 80 may be used as a connective tissue replacement (e.g., for a ligament, tendon, or linea alba), and the pattern 82 can be selected to provide desired strength, flexibility, or elastic properties to mimic nature tissue sites and/or to minimize failure rates after implantation.

The concentration, flow-rate, and specific enzyme or chemical used for cross-linking or proteolysis can be selected for a variety of reasons. For example, in general, the specific concentration and flow rate/time of exposure is selected based on the desired degree of cross-linking or proteolysis. In addition, since different enzymes and/or cross-linking agents may have proteolytic or cross-linking effects on different amino acids, combinations of two or more enzymes or cross-linking agents can be used.

Acellular Tissue Matrices

The methods of the present disclosure can be used to provide localized modification of properties of any tissue matrix, including the tissue matrix of cellularized tissues, partially decellularized tissue, or artificially manufactured matrices. In some embodiments, however, the tissue matrices include acellular tissue matrice. The term “acellular tissue matrix,” as used herein, refers generally to any tissue matrix that is substantially free of cells and/or cellular components.

Tissue matrices can be processed in a variety of ways, as described below to produce decellularized or partially decellularized tissues. The processing steps described below can be used along with and of (either before or after) the processes described herein for producing tissue matrices having variations mechanical and/or biological properties.

In general, the steps involved in the production of an acellular tissue matrix include harvesting the tissue from a donor (e.g., a human cadaver or animal source) and cell removal under conditions that preserve biological and structural function. In certain embodiments, the process includes chemical treatment to stabilize the tissue and avoid biochemical and structural degradation together with or before cell removal. In various embodiments, the stabilizing solution arrests and prevents osmotic, hypoxic, autolytic, and proteolytic degradation, protects against microbial contamination, and reduces mechanical damage that can occur with tissues that contain, for example, smooth muscle components (e.g., blood vessels). The stabilizing solution may contain an appropriate buffer, one or more antioxidants, one or more oncotic agents, one or more antibiotics, one or more protease inhibitors, and/or one or more smooth muscle relaxants.

The tissue is then placed in a decellularization solution to remove viable cells (e.g., epithelial cells, endothelial cells, smooth muscle cells, and fibroblasts) from the structural matrix without damaging the biological and structural integrity of the collagen matrix. The decellularization solution may contain an appropriate buffer, salt, an antibiotic, one or more detergents (e.g., TRITON X-100™, sodium deoxycholate, polyoxyethylene (20) sorbitan mono-oleate), one or more agents to prevent cross-linking, one or more protease inhibitors, and/or one or more enzymes. In some embodiments, the decellularization solution comprises 1% TRITON X-100™ in RPMI media with Gentamicin and 25 mM EDTA (ethylenediaminetetraacetic acid). In some embodiments, the tissue is incubated in the decellularization solution overnight at 37° C. with gentle shaking at 90 rpm. In certain embodiments, additional detergents may be used to remove fat from the tissue sample. For example, in some embodiments, 2% sodium deoxycholate is added to the decellularization solution.

Skin, parts of skin (e.g., dermis), and other tissues such as blood vessels, heart valves, fascia, cartilage, bone, and nerve connective tissue may be used to create acellular matrices within the scope of the present disclosure. Acellular tissue matrices can be tested or evaluated to determine if they are substantially free of cell and/or cellular components in a number of ways. For example, processed tissues can be inspected with light microscopy to determine if cells (live or dead) and/or cellular components remain. In addition, certain assays can be used to identify the presence of cells or cellular components. For example, DNA or other nucleic acid assays can be used to quantify remaining nuclear materials within the tissue matrices. Generally, the absence of remaining DNA or other nucleic acids will be indicative of complete decellularization (i.e., removal of cells and/or cellular components). Finally, other assays that identify cell-specific components (e.g., surface antigens) can be used to determine if the tissue matrices are acellular. Skin, parts of skin (e.g., dermis), and other tissues such as blood vessels, heart valves, fascia, cartilage, bone, and nerve connective tissue may be used to create acellular matrices within the scope of the present disclosure.

After the decellularization process, the tissue sample is washed thoroughly with saline. In some exemplary embodiments, e.g., when xenogenic material is used, the decellularized tissue is then treated overnight at room temperature with a deoxyribonuclease (DNase) solution. In some embodiments, the tissue sample is treated with a DNase solution prepared in DNase buffer (20 mM HEPES (4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid), 20 mM CaCl2 and 20 mM MgCl2). Optionally, an antibiotic solution (e.g., Gentamicin) may be added to the DNase solution. Any suitable buffer can be used as long as the buffer provides suitable DNase activity.

While an acellular tissue matrix may be made from one or more individuals of the same species as the recipient of the acellular tissue matrix graft, this is not necessarily the case. Thus, for example, an acellular tissue matrix may be made from porcine tissue and implanted in a human patient. Species that can serve as recipients of acellular tissue matrix and donors of tissues or organs for the production of the acellular tissue matrix include, without limitation, mammals, such as humans, nonhuman primates (e.g., monkeys, baboons, or chimpanzees), pigs, cows, horses, goats, sheep, dogs, cats, rabbits, guinea pigs, gerbils, hamsters, rats, or mice.

Elimination of the α-gal epitopes from the collagen-containing material may diminish the immune response against the collagen-containing material. The α-gal epitope is expressed in non-primate mammals and in New World monkeys (monkeys of South America) as well as on macromolecules such as proteoglycans of the extracellular components. U. Galili et al., J. Biol. Chem. 263: 17755 (1988). This epitope is absent in Old World primates (monkeys of Asia and Africa and apes) and humans, however. Id. Anti-gal antibodies are produced in humans and primates as a result of an immune response to α-gal epitope carbohydrate structures on gastrointestinal bacteria. U. Galili et al., Infect. Immun. 56: 1730 (1988); R. M. Hamadeh et al., J. Clin. Invest. 89: 1223 (1992).

Since non-primate mammals (e.g., pigs) produce α-gal epitopes, xenotransplantation of collagen-containing material from these mammals into primates often results in rejection because of primate anti-Gal binding to these epitopes on the collagen-containing material. The binding results in the destruction of the collagen-containing material by complement fixation and by antibody dependent cell cytotoxicity. U. Galili et al., Immunology Today 14: 480 (1993); M. Sandrin et al., Proc. Natl. Acad. Sci. USA 90: 11391 (1993); H. Good et al., Transplant. Proc. 24: 559 (1992); B. H. Collins et al., J. Immunol. 154: 5500 (1995). Furthermore, xenotransplantation results in major activation of the immune system to produce increased amounts of high affinity anti-gal antibodies. Accordingly, in some embodiments, when animals that produce α-gal epitopes are used as the tissue source, the substantial elimination of α-gal epitopes from cells and from extracellular components of the collagen-containing material, and the prevention of re-expression of cellular α-gal epitopes can diminish the immune response against the collagen-containing material associated with anti-gal antibody binding to α-gal epitopes.

To remove α-gal epitopes, after washing the tissue thoroughly with saline to remove the DNase solution, the tissue sample may be subjected to one or more enzymatic treatments to remove certain immunogenic antigens, if present in the sample. In some embodiments, the tissue sample may be treated with an α-galactosidase enzyme to eliminate α-gal epitopes if present in the tissue. In some embodiments, the tissue sample is treated with α-galactosidase at a concentration of 300 U/L prepared in 100 mM phosphate buffer at pH 6.0. In other embodiments, the concentration of α-galactosidase is increased to 400 U/L for adequate removal of the α-gal epitopes from the harvested tissue. Any suitable enzyme concentration and buffer can be used as long as sufficient removal of antigens is achieved.

Alternatively, rather than treating the tissue with enzymes, animals that have been genetically modified to lack one or more antigenic epitopes may be selected as the tissue source. For example, animals (e.g., pigs) that have been genetically engineered to lack the terminal α-galactose moiety can be selected as the tissue source. For descriptions of appropriate animals see co-pending U.S. application Ser. No. 10/896,594 and U.S. Pat. No. 6,166,288, the disclosures of which are incorporated herein by reference in their entirety. In addition, certain exemplary methods of processing tissues to produce acellular matrices with or without reduced amounts of or lacking alpha-1,3-galactose moieties, are described in Xu, Hui. et al., “A Porcine-Derived Acellular Dermal Scaffold that Supports Soft Tissue Regeneration: Removal of Terminal Galactose-α-(1,3)-Galactose and Retention of Matrix Structure,” Tissue Engineering, Vol. 15, 1-13 (2009), which is incorporated by reference in its entirety.

After the acellular tissue matrix is formed, histocompatible, viable cells may optionally be seeded in the acellular tissue matrix to produce a graft that may be further remodeled by the host. In some embodiments, histocompatible viable cells may be added to the matrices by standard in vitro cell co-culturing techniques prior to transplantation, or by in vivo repopulation following transplantation. In vivo repopulation can be by the recipient's own cells migrating into the acellular tissue matrix or by infusing or injecting cells obtained from the recipient or histocompatible cells from another donor into the acellular tissue matrix in situ. Various cell types can be used, including embryonic stem cells, adult stem cells (e.g. mesenchymal stem cells), and/or neuronal cells. In various embodiments, the cells can be directly applied to the inner portion of the acellular tissue matrix just before or after implantation. In certain embodiments, the cells can be placed within the acellular tissue matrix to be implanted, and cultured prior to implantation.

Patent Citations
Cited PatentFiling datePublication dateApplicantTitle
US458264022 Oct 198415 Apr 1986Collagen CorporationInjectable cross-linked collagen implant material
US490250811 Jul 198820 Feb 1990Purdue Research FoundationTissue graft composition
US496991218 Feb 198813 Nov 1990Kelman Charles DHuman collagen processing and autoimplant use
US510495728 Feb 199014 Apr 1992Autogenesis Technologies, Inc.Biologically compatible collagenous reaction product and articles useful as medical implants produced therefrom
US51318503 Nov 198921 Jul 1992Cryolife, Inc.Method for cryopreserving musculoskeletal tissues
US516031314 May 19913 Nov 1992Cryolife, Inc.Process for preparing tissue for transplantation
US523116926 Feb 199227 Jul 1993Norian CorporationMineralized collagen
US525413324 Apr 199119 Oct 1993Seid Arnold SSurgical implantation device and related method of use
US527582613 Nov 19924 Jan 1994Purdue Research FoundationFluidized intestinal submucosa and its use as an injectable tissue graft
US52846554 Feb 19928 Feb 1994Osteotech, Inc.Swollen demineralized bone particles, flowable osteogenic composition containing same and use of the composition in the repair of osseous defects
US533280211 Jun 199226 Jul 1994Autogenesis Technologies, Inc.Human collagen processing and autoimplant use
US533280416 Apr 199126 Jul 1994Synergen, Inc.High molecular weight human angiogenic basic fibroblast growth factors
US53366162 Feb 19939 Aug 1994Lifecell CorporationMethod for processing and preserving collagen-based tissues for transplantation
US536475616 Feb 199315 Nov 1994LifecellMethod of cryopreserving a suspension of biological material
US548930419 Apr 19946 Feb 1996Brigham & Women's HospitalMethod of skin regeneration using a collagen-glycosaminoglycan matrix and cultured epithelial autograft
US554768114 Jul 199420 Aug 1996Union Carbide Chemicals & Plastics Technology CorporationDermal patch
US56139825 Jun 199525 Mar 1997Cryolife, Inc.Method of preparing transplant tissue to reduce immunogenicity upon implantation
US56327785 Jun 199527 May 1997Cryolife, Inc.Treated tissue for implantation and methods of preparation
US564151810 Feb 199524 Jun 1997Purdue Research FoundationMethod of repairing bone tissue
US572875215 Mar 199617 Mar 1998Ethicon, Inc.Injectable microdipersions for soft tissue repair and augmentation
US573917618 Mar 199414 Apr 1998Atrix Laboratories, Inc.Biodegradable in-situ forming implants and methods of producing the same
US58005376 Jun 19951 Sep 1998Tissue Engineering, Inc.Method and construct for producing graft tissue from an extracellular matrix
US58938886 Sep 199413 Apr 1999Tissue Engineering, Inc.Method and construct for producing graft tissue from extracellular matrix
US59938448 May 199730 Nov 1999Organogenesis, Inc.Chemical treatment, without detergents or enzymes, of tissue to form an acellular, collagenous matrix
US60277432 Jun 199522 Feb 2000Stryker CorporationManufacture of autogenous replacement body parts
US60963474 Nov 19971 Aug 2000Purdue Research FoundationMyocardial graft constructs
US611362331 Dec 19975 Sep 2000Cabinet Beau De LomenieProsthetic device and method for eventration repair
US61662883 Jul 199626 Dec 2000Nextran Inc.Method of producing transgenic animals for xenotransplantation expressing both an enzyme masking or reducing the level of the gal epitope and a complement inhibitor
US617987217 Mar 199830 Jan 2001Tissue EngineeringBiopolymer matt for use in tissue repair and reconstruction
US619413613 Jul 199827 Feb 2001Lifecell CorporationCryoprotective solutions comprising DMSO, PG, 2,3-butanediol,raffinose and PVP
US63260187 Oct 19994 Dec 2001Musculoskeletal Transplant FoundationFlexible sheet of demineralized bone
US637199219 Dec 199716 Apr 2002The Regents Of The University Of CaliforniaAcellular matrix grafts: preparation and use
US638102615 Mar 199930 Apr 2002Lifecell Corp.Method of measuring the contour of a biological surface
US64327103 Oct 200013 Aug 2002Isolagen Technologies, Inc.Compositions for regenerating tissue that has deteriorated, and methods for using such compositions
US64857238 May 200026 Nov 2002Purdue Research FoundationEnhanced submucosal tissue graft constructs
US657626518 Oct 200010 Jun 2003Acell, Inc.Tissue regenerative composition, method of making, and method of use thereof
US666689227 May 199923 Dec 2003Cook Biotech IncorporatedMulti-formed collagenous biomaterial medical device
US68353856 May 200328 Dec 2004Carol J. BuckCompositions and methods for softening, thinning and removing hyperkeratotic tissue
US693332618 Jun 199923 Aug 2005Lifecell CoporationParticulate acellular tissue matrix
US735828420 Jan 200515 Apr 2008Lifecell CorporationParticulate acellular tissue matrix
US742532224 Sep 200416 Sep 2008Yissum Research Development Company Of The Hebrew University Of JerusalemResponsive biomedical composites
US749804012 Oct 20053 Mar 2009Lifenet HealthCompositions for repair of defects in osseous tissues, and methods of making the same
US749804112 Oct 20053 Mar 2009Lifenet HealthComposition for repair of defects in osseous tissues
US779976721 Feb 200321 Sep 2010Pioneer Surgical Orthobiologics, Inc.Cross-linked bioactive hydrogel matrices
US783802118 Jun 200423 Nov 2010Universite Paris 5Platforms, particularly prostheses, having biologically active coverings
US80671497 Jun 200229 Nov 2011Lifecell CorporationAcellular dermal matrix and method of use thereof for grafting
US8257372 *29 Dec 20094 Sep 2012Kci Licensing, Inc.System for providing fluid flow to nerve tissues
US832444916 Sep 20104 Dec 2012Lifecell CorporationAcellular tissue matrices made from alpha-1,3-galactose-deficient tissue
US92387935 Sep 201319 Jan 2016Lifecell CorporationMethod for enzymatic treatment of tissue products
US2002010354218 Sep 20011 Aug 2002Bilbo Patrick R.Methods for treating a patient using a bioengineered flat sheet graft prostheses
US200300358437 Jun 200220 Feb 2003Lifecell Corporation, A Delaware CorporationMethod for processing and preserving collagen-based tissues for transplantation
US2003014320718 Oct 200231 Jul 2003Livesey Stephen A.Remodeling of tissues and organ
US2004003773523 Aug 200226 Feb 2004Depaula Carl AlexanderAllograft tissue purification process for cleaning bone
US200401912264 Dec 200330 Sep 2004Badylak Stephen F.Method for repair of body wall
US2005002822821 Jul 20043 Feb 2005Lifecell CorporationAcellular tissue matrices made from alpa-1,3-galactose-deficient tissue
US2005015982220 Jan 200521 Jul 2005Lifecell Corporation, A Delaware CorporationParticulate acellular tissue matrix
US200600735926 Oct 20046 Apr 2006Wendell SunMethods of storing tissue matrices
US2006012737518 Jan 200615 Jun 2006Lifecell CorporationCryopreservation of human red blood cells
US2006015964127 Feb 200620 Jul 2006Biomedical Design, Inc.Variably crosslinked tissue
US200602109607 Jul 200521 Sep 2006Lifecell Corporation, A Texas CorporationMethod for processing and preserving collagen-based tissues for transplantation
US200602721024 Apr 20037 Dec 2006Novozymes North America, Inc.Strength and abrasion resistance of durable press finished cellulosic materials
US200700095867 Jul 200611 Jan 2007Cohen Kelman IWound dressings containing complexes of transition metals and alginate for elastase sequestering
US2007007852220 Jan 20055 Apr 2007Lifecell CorporationParticulate Acellular Tissue Matrix
US2007010475921 Dec 200610 May 2007Qlt Usa, Inc.Polymeric delivery formulations of leuprolide with improved efficacy
US2007024857519 Apr 200625 Oct 2007Jerome ConnorBone graft composition
US200800275429 May 200731 Jan 2008Lifecell CorporationReinforced Biological Tissue
US2008002756214 May 200731 Jan 2008Toshiya FujisatoMethod for preparing biological scaffold materials
US2009003528926 Sep 20065 Feb 2009Lifecell CorporationDry platelet composition
US2009013022128 Mar 200721 May 2009Fiona BollandDecellularisation of tissue matrices for bladder implantation
US2009023980911 Dec 200824 Sep 2009Food Industry Research And Development InstituteProcess For Preparing Peptide Products For Promoting Cholecystokinin Secretion And Use Of The Peptide Products
US200903067904 Jun 200910 Dec 2009Wendell SunElastase Treatment of Tissue Matrices
US2010002196110 Oct 200628 Jan 2010Japan Health Sciences FoundationMethod for preparing biological scaffold material
US2010004068713 Aug 200918 Feb 2010Kci Licensing, Inc.Tissue Scaffolds
US201002094083 Mar 201019 Aug 2010Lifecell CorporationRemodeling of Tissues and Organs
US2010023323517 Feb 201016 Sep 2010Matheny Robert GCompositions and methods for preventing cardiac arrhythmia
US201002727829 Jul 200828 Oct 2010Owens Rick TAcellular tissue matrix compositions for tissue repair
US2011002027120 May 201027 Jan 2011Humacyte, Inc.Elastin for soft tissue augmentation
US2011002175327 Jul 200927 Jan 2011National Cheng Kung UniversityMethod for Preparing Porous Collagen Matrices
US201200107287 Jul 201112 Jan 2012Lifecell CorporationMethod for shaping tissue matrices
US201200400139 Aug 201116 Feb 2012LifeCell Corporation.Regenerative Tissue Scaffolds
US201202520653 Apr 20124 Oct 2012Luis RozenszainAqueous process for preparing protein isolate and hydrolyzed protein from an oilseed
US2012026376313 Apr 201218 Oct 2012Lifecell CorporationRegenerative materials
US2012027621327 Apr 20121 Nov 2012Lifecell CorporationMethod for enzymatic treatment of tissue products
US201300130684 Jan 201010 Jan 2013James ForsellAcellular Dermal Allografts And Method Of Preparation
US2013005396014 Sep 201228 Feb 2013Lifecell CorporationReinforced biologic material
US201301219708 Nov 201216 May 2013Lifecell CorporationMethod for elimination of space through tissue approximation
US2013015867618 Dec 201220 Jun 2013Lifecell CorporationFlowable tissue products
US201400045495 Sep 20132 Jan 2014Lifecell CorporationMethod for Enzymatic Treatment of Tissue Products
US201403778335 Sep 201425 Dec 2014Lifecell CorporationMethod for enzymatic treatment of tissue products
CN1266716A12 Mar 199920 Sep 2000中国人民解放军第四军医大学第一附属医院Cross-linking type acellular pork skin
JP2004107303A Title not available
WO2001091671A11 Jun 20016 Dec 2001Crosscart, Inc.Xenograft heart valves
WO2002049687A114 Dec 200127 Jun 2002Vettivetpillai KetharanathanMethod of creating biological and biosynthetic material for implantation
WO2003017826A227 Aug 20026 Mar 2003Regeneration Technologies, Inc.Processed soft tissue for topical or internal application
WO2003032735A118 Oct 200224 Apr 2003Lifecell CorporationRemodeling of tissues and organs
WO2004020470A128 Feb 200311 Mar 2004Tissue Engineering Initiative Co., Ltd.Process for producing collagen treated with cysteine protease and collagen treated with cysteine protease
WO2005009134A121 Jul 20043 Feb 2005Lifecell CorporationACELLULAR TISSUE MATRICES MADE FROM GALACTOSE α-1,3-GALACTOSE-DEFICIENT TISSUE
WO2007043513A110 Oct 200619 Apr 2007Japan Health Sciences FoundationMethod for production of bio-derived scaffold
WO2009009620A29 Jul 200815 Jan 2009Lifecell CorporationAcellular tissue matrix compositions for tissue repair
WO2010019753A213 Aug 200918 Feb 2010Kci Licensing, Inc.Tissue scaffolds
WO2010078353A229 Dec 20098 Jul 2010Kci Licensing, Inc.Systems for providing fluid flow to tissues
WO2012142419A113 Apr 201218 Oct 2012Lifecell CorporationRegenerative materials
WO2012166784A130 May 20126 Dec 2012Lifecell CorporationAdipose tissue matrices
WO2013016571A126 Jul 201231 Jan 2013Harbor Medtech, Inc.Crosslinked human or animal tissue products and their methods of manufacture and use
Non-Patent Citations
Reference
1Ahn et al., "The past, present, and future of xenotransplantation" Yonsei Med J., 45(6):1017-1024 (Dec. 31, 2004).
2Allman et al., "Xenogeneic Extracellular Matrix Grafts Elicit a TH2-Restricted Immune Response" Transplantation, 71(11):1631-1640 (Jun. 15, 2001).
3Aycock et al., "Parastomal Hernia Repair With Acellular Dermal Matrix" J. Wound Ostomy Continence Nurs., 34(5):521-523 (2007).
4Badylak et al., "Endothelial cell adherence to small intestinal submucosa: An acellular bioscaffold" Biomaterials, 20:2257-2263 (1999).
5Badylak et al., "Extracellular Matrix As a Biological Scaffold Material: Structure and Function" Acta Biomaterialia, 5(1):1-13 (2009).
6Beniker et al., "The use of acellular dermal matrix as a scaffold for periosteum replacement" Orthopedics, 26(5 Suppl):s591-s596 (May 2003).
7Bruder et al., "The Effect of Implants Loaded with Autologous Mesenchymal Stem Cells on the Healing of Canine Segmental Bone Defects" J. Bone Joint Surg., 80:985-986 (1998).
8Buma et al., "Tissue engineering of the meniscus" Biomaterials, 25(9):1523-1532 (2004).
9Chaplin et al., "Use of an Acellular Dermal Allograft for Dural Replacement: An Experimental Study" Neurosurgery, 45(2):320-327 (Aug. 1999).
10Chen et al. "Acellular Collagen Matrix As a Possible 'Off the Shelf' Biomaterial for Urethral Repair" Urology, 54(3):407-410 (1999).
11Collins et al., "Cardiac xenografts between primate species provide evidence for the importance of the alpha-galactosyl determinant in hyperacute rejection" J. Immunol., 154:5500-5510 (1995).
12Collins et al., "Cardiac xenografts between primate species provide evidence for the importance of the α-galactosyl determinant in hyperacute rejection" J. Immunol., 154:5500-5510 (1995).
13Costantino et al., "Human Dural Replacement With Acellular Dermis: Clinical Results and a Review of the Literature" Head & Neck, 22:765-771 (Dec. 2000).
14Dobrin et al., "Elastase, collagenase, and the biaxial elastic properties of dog carotid artery" Am. J. Physiol. Heart Circ. Physiol., 247:H124-H131 (1984).
15Edel, "The use of a connective tissue graft for closure over an immediate implant covered with occlusive membrane" Clin. Oral Implants Res., 6:60-65 (1995) (Abstract).
16Fowler et al., "Ridge Preservation Utilizing an Acellular Dermal Allograft and Demineralized Freeze-Dried Bone Allograft: Part II. Immediate Endosseous Impact Placement" J. Periodontol., 71:1360-1364 (2000).
17Fowler et al., "Root Coverage with an Acellular Dermal Allograft: A Three-Month Case Report" J. Contemp. Dental Pract., 1(3):1-8 (2000).
18 *Galie et al., Simultaneous Application of interstitial flow and cyclic mechanical stain to three-dimensional cell seeded hydrogel, Tissue Engineering, Part C, vol. 17, 2011, p. 527-536.
19Galili et al., "Interaction Between Human Natural Anti-alpha-Galactosyl Immunoglobulin G and Bacteria of the Human Flora" Infect. Immun., 56(7):1730-1737 (1988).
20Galili et al., "Interaction Between Human Natural Anti-α-Galactosyl Immunoglobulin G and Bacteria of the Human Flora" Infect. Immun., 56(7):1730-1737 (1988).
21Galili et al., "Interaction of the Natural Anti-Gal Antibody with alpha-Galactosyl Epitopes: a Major Obstacle for Xenotransplantation in Humans" Immunology Today, 14(10):480-482 (1993).
22Galili et al., "Interaction of the Natural Anti-Gal Antibody with α-Galactosyl Epitopes: a Major Obstacle for Xenotransplantation in Humans" Immunology Today, 14(10):480-482 (1993).
23Galili et al., "Man, Apes, and Old World Monkeys Differ from Other Mammals in the Expression of alpha-Galactosyl Epitopes on Nucleated Cells" J. Biol. Chem., 263(33):17755-17762 (1988).
24Galili et al., "Man, Apes, and Old World Monkeys Differ from Other Mammals in the Expression of α-Galactosyl Epitopes on Nucleated Cells" J. Biol. Chem., 263(33):17755-17762 (1988).
25Gamba et al. "Experimental abdominal wall defect repaired with acellular matrix" Pediatr. Surg. Int., 18:327-331 (2002).
26Gebhart et al., "A radiographical and biomechanical study of demineralized bone matrix implanted into a bone defect of rat femurs with and without bone marrow" Acta Orthop. Belg., 57(2):130-143 (1991) (Abstract).
27Greenstein et al., "Parastomal Hernia Repair Using Cross-Linked Porcine Dermis: Report of a Case" Surg. Today, 38:1048-1051 (2008).
28Griffey et al., "Particulate Dermal Matrix as an Injectable Soft Tissue Replacement Material" J. Biomed. Mater. Res. (Appl. Biomater.), 58(1):10-15 (2001).
29Hamadeh et al., "Human natural anti-Gal IgG regulates alternative complement pathway activation on bacterial surfaces," J. Clin. Invest. 89:1223-1235 (1992).
30Harris, "A Comparative Study of Root Coverage Obtained with an Acellular Dermal Matrix Versus a Connective Tissue Graft: Results of 107 Recession Defects in 50 Consecutively Treated Patients" Int. J. Periodontics Restorative Dentist., 20(1):51-59 (2000).
31Harris, "Root Coverage With a Connective Tissue With Partial Thickness Double Pedicle Graft and an Acellular Dermal Matrix Graft: A Clinical and Histological Evaluation of a Case Report" J. Periodontol., 69:1305-1311 (1998).
32International Search Report and Written Opinion, dated: Jul. 16, 2014, for International Patent Application No. PCT/US2014/012854.
33Ionescu et al., "Effect of Papain and Bromelin on Muscle and Collagen Proteins in Beef Meat," The Annals of the University Dunarea de Jos of Galati. Fascicle VI, Food Technology, New Series, pp. 9-16, 2008.
34Karlinsky et al., "In Vitro Effects of Elastase and Collagenase on Mechanical Properties of Hamster Lungs," Chest, 69 (2):275-276 (1976).
35Kish et al., "Acellular Dermal Matrix (AlloDerm): New Material in the Repair of Stoma Site Hernias" The American Surgeon, 71:1047-1050 (Dec. 2005).
36Kridel et al., "Septal Perforation Repair with Acellular Human Dermal Allograft" Arch. Otolaryngol. Head Neck Surg., 124:73-78 (Jan. 1998).
37Laidlaw et al., "Tympanic Membrane Repair With a Dermal Allograft" Laryngoscope, 111:702-707 (Apr. 2001).
38Lee et al., "In vitro evaluation of a poly(lactide-co-glycolide)-collagen composite scaffold for bone regeneration" Biomaterials, 27:3466-3472 (2006).
39Lu et al., "Novel Porous Aortic Elastin and Collagen Scaffolds for Tissue Engineering" Biomaterials, 25(22):5227-5237 (2004).
40Reihsner et al., "Biomechanical properties of elastase treated palmar aponeuroses," Connective Tissue Research, 26:77-86 (1991).
41Simon et al., "Early failure of the tissue engineered porcine heart valve SYNERGRAFT(TM) in pediatric patients" Eur. J. Cardiothorac. Surg., 23(6)1002-1006 (2003).
42Simon et al., "Early failure of the tissue engineered porcine heart valve SYNERGRAFT™ in pediatric patients" Eur. J. Cardiothorac. Surg., 23(6)1002-1006 (2003).
43Tedder et al., "Stabilized Collagen Scaffolds for Heart Valve Tissue Engineering," Tissue Engineering: Part A, pp. 1-12 (2008).
44Xu, "A Porcine-Derived Acellular Dermal Scaffold that Supports Soft Tissue Regeneration: Removal of Terminal Galactose-?-(1,3)-Galactose and Retention of Matrix Structure," Tissue Engineering, vol. 15, 1-13 (2009).
45Yuan et al., "Effects of collagenase and elastase on the mechanical properties of lung tissue strips," J. App. Physiol., 89:3-14 (2000).
46Zheng et al. "Porcine small intestine submucosa (SIS) is not an acellular collagenous matrix and contains porcine DNA: Possible implications in human implantation" J. Biomed. Mater. Res. B: Appl. Biomater., 73(1):61-67 (2005).
Classifications
International ClassificationA61K35/12, A61L27/36
Cooperative ClassificationA61L27/24, A61L27/3687, A61K35/12
Legal Events
DateCodeEventDescription
9 Sep 2015ASAssignment
Owner name: LIFECELL CORPORATION, NEW JERSEY
Free format text: ASSIGNMENT OF ASSIGNORS INTEREST;ASSIGNORS:MONTEIRO, GARY;WAGNER, CHRISTOPHER T.;RODRIGUEZ, NEIL L.;AND OTHERS;SIGNING DATES FROM 20150327 TO 20150406;REEL/FRAME:036517/0740
17 Feb 2016ASAssignment
Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, MINNESOTA
Free format text: SECURITY INTEREST;ASSIGNORS:KINETIC CONCEPTS, INC.;KCI USA, INC.;ACELITY L.P. INC.;AND OTHERS;REEL/FRAME:037845/0497
Effective date: 20160209
21 Sep 2016ASAssignment
Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATE
Free format text: SECOND LIEN SECURITY AGREEMENT;ASSIGNORS:KCI USA, INC.;LIFECELL CORPORATION;KCI LICENSING, INC.;REEL/FRAME:040098/0268
Effective date: 20160920
7 Oct 2016ASAssignment
Owner name: WILMINGTON TRUST, NATIONAL ASSOCIATION, AS COLLATE
Free format text: LIMITED THIRD LIEN INTELLECTUAL PROPERTY SECURITY AGREEMENT;ASSIGNORS:KCI USA, INC.;LIFECELL CORPORATION;KCI LICENSING, INC.;REEL/FRAME:040291/0237
Effective date: 20161006
2 Feb 2017ASAssignment
Owner name: LIFECELL CORPORATION, NEW JERSEY
Free format text: RELEASE OF SECURITY INTEREST 040291/0237;ASSIGNOR:WILMINGTON TRUST;REEL/FRAME:041608/0702
Effective date: 20170131
Owner name: LIFECELL CORPORATION, NEW JERSEY
Free format text: RELEASE OF SECURITY INTEREST 037845/0497;ASSIGNOR:WILMINGTON TRUST;REEL/FRAME:041608/0603
Effective date: 20170131
Owner name: LIFECELL CORPORATION, NEW JERSEY
Free format text: RELEASE OF SECURITY INTEREST 040098/0268;ASSIGNOR:WILMINGTON TRUST;REEL/FRAME:041608/0554
Effective date: 20170131